Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease

NCT02651272 is registered in ClinicalTrials.gov with Boston University as lead sponsor.

NCT NCT02651272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02651272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease
Lead sponsor
Boston University
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2015
Completion date
December 18, 2019
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension, sickle cell disease